Latest News Releases From The Newsroom
Breaking: Vivos Therapeutics Strikes Deals; RPM Beats Wall Street Estimates
October 04th, 2023
Shares of Vivos Therapeutics, Inc. (Nasdaq: VVOS) surged by more than 40% in pre-market trading following the announcement of strategic agreements with Ormco and On Demand Orthodontist. These agreements pave the way for Spark Clear Aligners to be off. Read more
Acuity Brands Posts Mixed Results; Sanofi, Teva Ink Anti-TL1A Therapy Deal
October 04th, 2023
Acuity Brands, Inc. (NYSE: AYI) posted fourth-quarter fiscal 2023 earnings of $3.97 per share, surpassing the consensus EPS estimate of $3.72. Quarterly sales for the company totaled $1.01 billion, slightly below analysts' revenue projections of $1.0. Read more
Fluor, LyondellBasell, and DT Midstream: Bullish Views
October 04th, 2023
UBS upgraded Fluor Corporation (NYSE: FLR), a leading engineering and construction company, from Neutral to Buy and raised the price target from $35 to $47 With $FLR closing at $34.62 on Tuesday, the new price target implies a potential upside of . Read more
Brooge Energy Becomes Takeover Target; A10 Networks Sees Below-Consensus Revenue
October 03rd, 2023
Shares of Brooge Energy Ltd. (Nasdaq: BROG) surged by more than 20% in after-hours trading as Gulf Navigation Holdings PJSC (GULFNAV), a Dubai-based maritime and shipping company, submitted a formal proposal to fully acquire all of Brooge Energy Limi. Read more
ALX Oncology's Evorpacept Data Sparks Momentum; McCormick Q3 Sales Miss
October 03rd, 2023
Shares of ALX Oncology Holdings Inc. (Nasdaq: ALXO) surged by more than 100% in pre-market trading after the company unveiled positive interim Phase 2 data from the ASPEN-06 clinical trial evaluating its CD47 blocking therapeutic evorpacept in combin. Read more
Momentum Builds for ALX Oncology and Delta Apparel
October 03rd, 2023
Shares of ALX Oncology Holdings Inc. (Nasdaq: ALXO) surged by more than 20% in after-hours trading following the announcement that it will unveil interim Phase 2 ASPEN-06 clinical trial results of evorpacept, aimed at treating advanced HER2-positive . Read more
Lockheed Martin, Boeing, and Northrop Grumman: Defense Contracts Wins
October 02nd, 2023
Lockheed Martin Rotary and Mission Systems, a business segment of Lockheed Martin Corporation (NYSE: LMT), has been granted a $10,854,384 cost-plus-fixed-fee modification to a previously awarded contract for Extra Large Unmanned Undersea Vehicle engi. Read more
Market Buzz: CDI Trial Outcome Fuels Acurx Pharmaceuticals
October 02nd, 2023
Shares of Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) surged by more than 20% in pre-market trading following the company's decision to discontinue its Phase 2b clinical trial of ibezapolstat, its lead antibiotic candidate, designed for the treatment . Read more
Bullish Views for Nextracker and Sunnova Energy
October 02nd, 2023
UBS has initiated coverage on Nextracker Inc. (Nasdaq: NXT), a notable player in the energy technology sector, with a Buy rating and a price target of $50. Closing at $40.16 on Friday, this price target suggests a substantial potential upside of $. Read more
Earnings Countdown: Lamb Weston, Conagra Brands, and Levi Strauss in Focus
October 01st, 2023
Some companies scheduled to disclose their financial results on Thursday, October 5, are: Lamb Weston Holdings, Inc. (NYSE: LW), a key player in the food industry, will release its fiscal first-quarter 2024 financial results before the market open. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
A Preview: Oracle, Franco-Nevada, and Asana Earnings Due
March 09th, 2025NVIDIA, Salesforce, and Agilent Technologies Earnings Loom: What to Expect
February 23rd, 2025Key Reports Ahead: KBR, Hims & Hers Health, and Cleveland-Cliffs Earnings Preview
February 23rd, 2025Earnings On Deck: What to Expect from Copart, Cheniere Energy, and Insulet
February 16th, 2025
Member Login